Uric acid as a marker for renal dysfunction in hypertensive women on diuretic and nondiuretic therapy

Journal of Clinical Hypertension

Volumn 11, Issue 5, 2009, Pages 253-259

  Borges, Rodolfo L ^a,b   Hirota, Andrea H ^a   Quinto, Beata M ^a   Ribeiro, Artur B ^a   Zanella, Maria T ^a   Batista, Marcelo C ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CREATININE; DIURETIC AGENT; FUROSEMIDE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; TRIACYLGLYCEROL; URIC ACID;

ADULT; ALBUMINURIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY HEIGHT; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; HYPERURICEMIA; INSULIN RESISTANCE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; WAIST CIRCUMFERENCE; WOMEN'S HEALTH;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; CREATININE; CROSS-SECTIONAL STUDIES; DIURETICS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; HYPERURICEMIA; KIDNEY; KIDNEY DISEASES; LIPIDS; MIDDLE AGED; RISK FACTORS; URIC ACID;

EID: 66649126634     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2009.00101.x     Document Type: Article

References (43)

1. Cannon PJ, Stason WB, Demartini FE, et al. Hyperuricemia in primary and renal hypertension. N Engl J Med. 1966;275:457-464.
2. Kinsey D, Walther R, Sise HS, et al. Incidence of hyperuricemia in 400 hypertensive subjects. Circulation. 1961;24:972-973.
3. Tykarski A. Evaluation of renal handling of uric acid in essential hypertension: Hyperuricemia related to decreased urate secretion Nephron. 1991;59:364-368.
4. Messerli FH, Frohlich ED, Dreslinki DR, et al. Serum uric acid in essential hypertension: An indicator of renal vascular involvement. Ann Intern Med. 1980;93:817-821.
5. Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism. 1990;39:167-174.
6. Muscelli E, Natali A, Bianchi S, et al. Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens. 1996;9:746-752.
7. Kahn AM. Effect of diuretics on the renal handling of urate. Semin Nephrol. 1988;8(3):305-314.
8. Carlsen JE, Kober L, Torp-Pedersen C, et al. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ. 1990;300:975-978.
9. Rathmann W, Funkhouser E, Dyer AR, et al. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: The CARDIA study (Coronary Artery Risk Development in Young Adults). Ann Epidemiol. 1998;8:250-261.
10. Culleton BR, Larson MG, Kannel WB, et al. Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann Intern Med. 1999;131(1):7-13.
11. Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38:1101-1106.
12. Sánchez-Lozada LG, Tapia E, Avila-Casado C, et al. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol. 2002;283:F1105-F1110.
13. Sánchez-Lozada LG, Tapia E, Santamaria J, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int. 2005;67:237-245.
14. Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002;13(12):2888-2897.
15. Ishani A, Grandits GA, Grimm RH, et al. Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. J Am Soc Nephrol. 2006;17:1444-1452.
16. Chonchol MB, Shlipak MG, Katz R, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis. 2007;50:239-247.
17. Moriarity JT, Folsom AR, Iribarren C, et al. Serum uric acid and risk of coronary heart disease: Therosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol. 2000;10:136-143.
18. Alderman MH, Cohen H, Madhavan S, et al. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension. 1999;34:144-150.
19. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA. 2003;289(19):2560-2572.
20. Iseki K, Ikemiya Y, Inoue T, et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004;44:642-650.
21. Matsumura K, Ohtsubo T, Oniki Hideyuki, et al. Gender-related association of serum uric acid and left ventricular hypertrophy in hypertension. Circ J. 2006;70:885-888.
22. Freedman DS, Williamson DF, Gunter EW, et al. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol. 1995;141:637-644.
23. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002;106;3143-3421.
24. American Diabetes Association. Standards of medical care in diabetes - 2006. Diab Care. 2006;29:S4-S85.
25. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome: A new world-wide definition: A consensus statement from the International Diabetes Federation. Diabet Med. 2006;23:469-480.
26. Levey SA, Coresh J, Greene T, et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53(4):766-772.
27. Levey AS, Coresh J, Balk E, et al; National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137-147.
28. Myers GL, Miller WG, Coresh J, et al. Recommendations for improving serum creatinine measurement: A report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem. 2006;52:5-18.
29. Sierra-Johnson J, Romero-Corral A, Somers VK, et al. ApoB/Apo A-I ratio: an independent predictor of insulin resistance in US non-diabetic subjects. Eur Heart J. 2007;28:2637-2643.
30. McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003;139(10):802-809.
31. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
32. Vaziri ND, Freel RW, Hatch M. Effect of chronic experimental renal insufficiency on urate metabolism. J Am Soc Nephrol. 1995;6:1313-1317.
33. Nicholls A, Snaith ML, Scott JT. Effect of oestrogen therapy on plasma and urinary levels of uric acid. BMJ. 1973;1:449-451.
34. Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure independent mechanism. Am J Physiol Renal Physiol. 2002;282:F991-F997.
35. Siu YP, Leung KT, Tong MK, et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47(1):51-59.
36. Kanbay M, Ozkara A, Selcoki Y, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int J Urol. 2007;39(4):1227-1233.
37. George J, Carr E, Davies J, et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114:2508-2516.
38. Thompson A, Daneson J. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: A literature-based metanalysis of prospective studies. J Intern Med. 2006;259(5):481-492.
39. Jeppesen J, Hein HO, Suadicani P, et al. Low triglycerides- high high-density lipoprotein cholesterol and risk of ischemic heart disease. Arch Intern Med. 2001;161(3):361-366.
40. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685-1695.
41. Kang DH, Park SK, Lee IK, et al. Uric acid-induced C-reactive protein expression: Implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 2005;16(12):3553-3562.
42. Eriksson JW, Jansson PA, Carlberg Bo, et al. Hydrochlorothiazide, but not candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: The mechanisms for the diabetes preventing effect of candesartan (MEDICA) study. Hypertension. 2008;52(6):1030-1037.
43. Franse LV, Pahor M, di Bari M, et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens. 2000;18:1149-1154.